Loading patent…
AssigneeTrustees of Boston University
InventorNader Rahimi
Estimating the term…
The present invention provides methods and compositions for the treatment and prevention of angiogenesis, or cancer, e.g., metastatic cancer by administering an effective amount of an inhibitor of immunoglobulin containing proline rich receptor-1 (IGPR-1) protein or expression. In particular, the present invention provides methods and compositions for the treatment and prevention of cancer by administering an effective amount of an inhibitor of immunoglobulin containing proline rich receptor-1 (IGPR-1) protein or expression which is a soluble extracellular domain IGPR-1. Another aspects relates to methods and compositions comprising a IGPR-1 polypeptide or functional fragment thereof to promote angiogenesis in a subject in need thereof, e.g., for treatment of infarcts, retinopathy, AMD and the like.
A method of inhibiting angiogenesis in a subject, comprising administering to the subject a composition comprising an inhibitor of the immunoglobulin containing proline rich receptor-1 (IGPR-1) polypeptide.
A method of treating cancer in a subject at risk thereof, comprising administering to the subject an effective amount of a composition comprising an inhibitor of immunoglobulin containing proline rich receptor-1 (IGPR-1) protein or expression for the treatment and/or prevention of a malignancy or neoplasia disorder in the subject.
-60. (canceled)
A method to promote angiogenesis in a subject in need thereof, comprising administering to a subject a composition comprising an IGPR-1 polypeptide comprising amino acids of SEQ ID NO:
A soluble extracellular domain of IGPR-1 for inhibiting angiogenesis or endothelial cell migration in a subject in need thereof, wherein the soluble extracellular domain of IGPR-1 inhibits IGPR-1 polypeptide function and/or cis-dimerization.
A dominant negative inhibitor of IGPR-1 comprising at least about 60 C-terminal amino acids of SEQ ID NO:
Dependencies are inferred from the claim text.